## Alberto Chiesa

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/565229/publications.pdf

Version: 2024-02-01

72 papers 6,895 citations

147801 31 h-index 71 g-index

74 all docs

74 docs citations

times ranked

74

7081 citing authors

#	Article	IF	CITATIONS
1	Mindfulness-Based Stress Reduction for Stress Management in Healthy People: A Review and Meta-Analysis. Journal of Alternative and Complementary Medicine, 2009, 15, 593-600.	2.1	1,232
2	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clinical Psychology Review, 2011, 31, 449-464.	11.4	946
3	A systematic review of neurobiological and clinical features of mindfulness meditations. Psychological Medicine, 2010, 40, 1239-1252.	4.5	533
4	Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis. Psychiatry Research, 2011, 187, 441-453.	3.3	518
5	Treatment-Emergent Sexual Dysfunction Related to Antidepressants. Journal of Clinical Psychopharmacology, 2009, 29, 259-266.	1.4	455
6	Mindfulness: Top–down or bottom–up emotion regulation strategy?. Clinical Psychology Review, 2013, 33, 82-96.	11.4	328
7	Mindfulnessâ€based approaches: are they all the same?. Journal of Clinical Psychology, 2011, 67, 404-424.	1.9	311
8	Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence. Journal of Alternative and Complementary Medicine, 2011, 17, 83-93.	2.1	281
9	Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence. Substance Use and Misuse, 2014, 49, 492-512.	1.4	262
10	The Difficulty of Defining Mindfulness: Current Thought and Critical Issues. Mindfulness, 2013, 4, 255-268.	2.8	212
11	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. International Clinical Psychopharmacology, 2011, 26, 130-140.	1.7	148
12	Vipassana Meditation: Systematic Review of Current Evidence. Journal of Alternative and Complementary Medicine, 2010, 16, 37-46.	2.1	91
13	Psychological Mechanisms of Mindfulness-Based Interventions. Holistic Nursing Practice, 2014, 28, 124-148.	0.7	88
14	Effectiveness of traditional meditation retreats: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2017, 92, 16-25.	2.6	82
15	Sexual Side Effects of Pharmacological Treatment of Psychiatric Diseases. Clinical Pharmacology and Therapeutics, 2011, 89, 142-147.	4.7	77
16	Embodied Mindfulness. Mindfulness, 2017, 8, 1160-1171.	2.8	77
17	Disentangling the neural mechanisms involved in Hinduism- and Buddhism-related meditations. Brain and Cognition, 2014, 90, 32-40.	1.8	71
18	Zen Meditation: An Integration of Current Evidence. Journal of Alternative and Complementary Medicine, 2009, 15, 585-592.	2.1	64

#	Article	IF	CITATIONS
19	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Research, 2015, 226, 474-483.	3.3	54
20	Safety and Tolerability of Lamotrigine. Clinical Neuropharmacology, 2011, 34, 39-47.	0.7	53
21	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. Neuropsychobiology, 2012, 65, 1-11.	1.9	53
22	Newer antidepressants and panic disorder. International Clinical Psychopharmacology, 2013, 28, 33-45.	1.7	50
23	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. European Neuropsychopharmacology, 2009, 19, 562-570.	0.7	49
24	Mindfulness-Based Cognitive Therapy Versus Psycho-Education for Patients with Major Depression Who Did Not Achieve Remission Following Antidepressant Treatment: A Preliminary Analysis. Journal of Alternative and Complementary Medicine, 2012, 18, 756-760.	2.1	49
25	Associations Between Mindfulness and Emotion Regulation: the Key Role of Describing and Nonreactivity. Mindfulness, 2019, 10, 366-375.	2.8	49
26	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of Affective Disorders, 2011, 128, 56-63.	4.1	45
27	Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression. Journal of Clinical Psychopharmacology, 2015, 35, 296-303.	1.4	44
28	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	1.7	42
29	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	3.3	42
30	Quetiapine for bipolar depression. International Clinical Psychopharmacology, 2012, 27, 76-90.	1.7	40
31	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. Acta Neuropsychiatrica, 2010, 22, 104-117.	2.1	36
32	COMT and age at onset in mood disorders: A replication and extension study. Neuroscience Letters, 2011, 498, 218-221.	2.1	32
33	Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 199-205.	3.2	31
34	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 305-311.	3.2	30
35	Citation patterns and trends of systematic reviews about mindfulness. Complementary Therapies in Clinical Practice, 2017, 28, 26-37.	1.7	29
36	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, 2010, 44, 598-604.	3.1	25

#	Article	IF	CITATIONS
37	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 93-103.	3.2	24
38	Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Research, 2012, 198, 39-46.	3.3	23
39	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. Neuropsychobiology, 2012, 65, 70-75.	1.9	22
40	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Research, 2013, 209, 121-123.	3.3	22
41	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. Neuropsychobiology, 2011, 63, 1-7.	1.9	20
42	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	4.0	19
43	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International Journal of Psychiatry in Clinical Practice, 2014, 18, 97-102.	2.4	19
44	Neuro-imaging of mindfulness meditations: implications for clinical practice. Epidemiology and Psychiatric Sciences, 2011, 20, 205-210.	3.9	17
45	Association between the estrogen receptor TA polymorphism and Harm avoidance. Neuroscience Letters, 2009, 467, 155-158.	2.1	16
46	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neuroscience Letters, 2012, 506, 170-174.	2.1	15
47	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	2.8	14
48	Predictors of Early Worsening after Switch to Aripiprazole. Clinical Drug Investigation, 2010, 30, 187-193.	2.2	13
49	Improving psychotherapy research: The example of mindfulness based interventions. World Journal of Methodology, 2011, 1, 4.	3.5	12
50	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 434-438.	1.7	10
51	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. Psychiatry Research, 2010, 179, 222-225.	3.3	10
52	Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression. Clinical Drug Investigation, 2011, 31, 385-405.	2.2	10
53	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Research, 2011, 188, 166-169.	3.3	10
54	Influence of TAAR6 polymorphisms on response to aripiprazole. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 822-826.	4.8	9

#	Article	IF	CITATIONS
55	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry Research, 2010, 178, 430-432.	3.3	9
56	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. Neuroscience Letters, 2012, 508, 37-41.	2.1	9
57	Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2012, 16, 18-26.	2.4	8
58	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.7	8
59	Family history of major depression and residual symptoms in responder and non-responder depressed patients. Comprehensive Psychiatry, 2014, 55, 51-55.	3.1	8
60	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	1.0	7
61	No influence of FAT polymorphisms in response to aripiprazole. Journal of Human Genetics, 2010, 55, 32-36.	2.3	6
62	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Neuropsychobiology, 2010, 62, 245-249.	1.9	5
63	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. Journal of International Medical Research, 2012, 40, 258-265.	1.0	5
64	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	2.4	4
65	The challenge of uncovering the genetics of anxiety. Acta Psychiatrica Scandinavica, 2012, 125, 185-186.	4.5	3
66	No influence of <i>SLC6A3 </i> 40 base VNTR polymorphism on the response to risperidone. International Journal of Psychiatry in Clinical Practice, 2010, 14, 228-232.	2.4	2
67	Social adjustment among treatment responder patients with mood disorders. Journal of Affective Disorders, 2013, 150, 961-966.	4.1	2
68	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	1.6	2
69	Clinical Roundup: How Do You Treat Insomnia in Your Practice?â€"Part 1. Alternative and Complementary Therapies, 2010, 16, 242-245.	0.1	1
70	Letter to the Editor: Response to â€~A systematic review of neurobiological and clinical features of mindfulness meditations'. Psychological Medicine, 2011, 41, 666-668.	4.5	1
71	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. Mindfulness, 2021, 12, 2059-2075.	2.8	1
72	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials― Psychiatry Research, 2013, 207, 232-233.	3.3	0